Kedudukan dalam Saham
#24699
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on... ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells. These treatments target various types of cancer and rare (orphan) diseases, with the company operating in both France and the United States. Its primary experimental drug, eryaspase, is currently undergoing Phase 3 clinical trials for patients battling second-line pancreatic cancer. Furthermore, this candidate is also in Phase 2 development for triple-negative breast cancer and for individuals with second-line acute lymphoblastic leukemia. The company is additionally advancing erymethionase, a preclinical-stage product. This candidate utilizes methionine-gamma-lyase, encased within red blood cells, to specifically address cancers that are dependent on methionine for growth. Established in 2004, ERYTECH Pharma's corporate headquarters are situated in Lyon, France.
Harga Saham
$0.95011029
Disegerakkan terakhir: 2023-06-28
Perubahan (1 tahun)
0.00%
Perdagangan ERYTECH Pharma S.A. (ERYP)
Harga ERYP dengan permodalan pasaran b
Modal pasaran bagi ERYTECH Pharma S.A.(ERYP)
Modal Pasaran: $57.72M
Sehingga August 2026, ERYTECH Pharma S.A. mempunyai modal pasaran sebanyak $57.72M. Ini menjadikan ERYTECH Pharma S.A. syarikat ke-24699th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran ERYTECH Pharma S.A. dari 2013 hingga 2026
ERYP berbanding dengan 5 teratas yang paling popular stocks
| Harga ERYP |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.246T
|
+9,089,404.83%
|
|
|
|
|
$4.577T
|
+7,929,743.94%
|
|
|
|
|
$4.156T
|
+7,200,429.00%
|
|
|
|
|
$3.606T
|
+6,247,012.10%
|
|
|
|
|
$2.805T
|
+4,860,450.97%
|
